AbbVie (ABBV) Dividend Coverage Ratio Growth (1y) (2014 - 2026)
Powered by 
Analysis
AbbVie (ABBV) Dividend Coverage Ratio Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.24 Bn | 625.48 Bn | 17.26 Bn | -3.09% |
| 2 | AbbVie | 441.52 Bn | 434.96 Bn | 12.70 Bn | 264.24% |
| 3 | Merck | 365.75 Bn | 358.60 Bn | 12.21 Bn | -129.25% |
| 4 | Novartis Ag | 266.61 Bn | 258.92 Bn | 11.24 Bn | -30.09% |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -92.21% |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.43 Bn | 18.77 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 264.24% |
| Mar 31, 2026 | -48.75% |
| Dec 31, 2025 | 7,560.28% |
| Sep 30, 2025 | -88.64% |
| Jun 30, 2025 | -35.23% |
| Mar 31, 2025 | -10.96% |
| Dec 31, 2024 | -102.66% |
| Sep 30, 2024 | -16.14% |
| Jun 30, 2024 | -35.34% |
| Mar 31, 2024 | 1,457.79% |
| Dec 31, 2023 | -68.19% |
| Sep 30, 2023 | -57.04% |
| Jun 30, 2023 | 108.61% |
| Mar 31, 2023 | -102.05% |
| Dec 31, 2022 | -43.57% |
| Sep 30, 2022 | 14.90% |
| Jun 30, 2022 | 11.19% |
| Mar 31, 2022 | 16.18% |
| Dec 31, 2021 | 9,564.91% |
| Sep 30, 2021 | 24.72% |